查加斯病治疗市场（2026—2031）
查加斯病治疗市场规模预计由2026年的5.5亿美元增至2031年的8亿美元，预测期复合年增长率为7.80%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
查加斯病治疗市场规模预计由2026年的5.5亿美元增至2031年的8亿美元，预测期复合年增长率为7.80%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 7.8% | 机构预测 |
| 市场规模 | 2026 | USD 0.55 billion | 机构预测 |
| 市场规模 | 2031 | USD 0.8 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease_phase_and_clinical_form | chronic Chagas disease | 2025 | 65.770% |
| dosage_form | tablets | 2025 | 75.600% |
| end_user | hospitals | 2025 | 57.660% |
| geography | North America | 2025 | 39.440% |
| product_type | benznidazole | 2025 | 68.400% |
| treatment_type | etiological antiparasitic treatment | 2025 | 61.450% |
关键结论
- disease_phase_and_clinical_form 维度中，chronic Chagas disease 在 2025 年的公开份额为 65.77%。
- dosage_form 维度中，tablets 在 2025 年的公开份额为 75.6%。
- end_user 维度中，hospitals 在 2025 年的公开份额为 57.66%。
- geography 维度中，North America 在 2025 年的公开份额为 39.44%。
- product_type 维度中，benznidazole 在 2025 年的公开份额为 68.4%。
- treatment_type 维度中，etiological antiparasitic treatment 在 2025 年的公开份额为 61.45%。
主要参与者
- GlaxoSmithKline plc
- Bayer AG
- Novartis AG
- Sanofi
- F. Hoffmann-La Roche Ltd
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Screening of migrant and at-risk populations | +1.500% | North America and Europe | Short term (≤ 2 years) |
| Expansion of congenital chagas test-and-treat programs | +1.100% | Latin America, North America, and Europe | Short term (≤ 2 years) |
| Who and paho drug access and elimination programs | +1.300% | Global, including 21 endemic countries in the Americas | Medium term (2-4 years) |
| Commercialization of pediatric benznidazole presentations | +1.200% | Latin America and North America | Short term (≤ 2 years) |
| Decentralized care pathways and remote-area treatment delivery | +1.000% | South America and Central America | Medium term (2-4 years) |
| Shorter-duration and lower-dose regimen development | +0.800% | Global | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Asymptomatic infection and low diagnosis-to-treatment conversion | -1.300% | Global, with the highest relevance in Latin America | Short term (≤ 2 years) |
| Adverse-event burden and treatment discontinuation | -1.000% | Global | Medium term (2-4 years) |
| Fragile and donor-dependent product supply chains | -0.800% | South America and the Middle East and Africa | Medium term (2-4 years) |
| Weak commercial incentives for new chemical entities | -0.600% | Global | Long term (≥ 4 years) |
报告关注的关键问题
What is the projected value of the Chagas disease treatment market by 2031?
The Chagas disease treatment market is projected to reach USD 0.80 billion by 2031, from USD 0.55 billion in 2026, at a CAGR of 7.80%.
Which Chagas disease therapy holds the largest revenue share?
Benznidazole held 68.40% of product-type revenue in 2025, supported by its established role as a first-line therapy.
Which Chagas disease therapy is growing fastest?
Nifurtimox is forecast to grow at a 10.23% CAGR through 2031, supported by pediatric access and recent regulatory progress.
What is driving demand for Chagas disease treatment?
Expanded migrant screening, congenital test-and-treat programs, and pediatric formulations are increasing the number of patients who can enter care.
Which region leads Chagas disease treatment revenue?
North America held 39.44% of revenue in 2025, supported by specialist care networks and commercial reimbursement.
What limits wider treatment access for Chagas disease?
Low diagnosis rates, asymptomatic infection, treatment adverse events, and donor-dependent supply chains restrict access and treatment completion.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence